← SynDRA
ENSARTINIB
SynDRA canonical compound SYN0039294 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | alk inihibitor |
|---|
| Indication | non-small cell lung cancer (nsclc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- alk inihibitor
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
Cross-references
Synonyms
- X-396
- Ensacove
- ALK inhibitors (cancer)
- X-276
- X-353
- X-376
- ALK inhibitors (cancer), Xcovery
- Anaplastic lymphoma kinase inhibitors (cancer), Xcovery
- SMA5ZS5B22
- ensartinibum
- RefChem:136992
- Ensartinib (X-396)
- Ensartinib [INN]
- X396
- Ensartinib (USAN)
- ENSARTINIB [USAN]
- C26H27Cl2FN6O3
- Ensartinib; X-396
- X-396(Ensartinib)
- Ensartinib [USAN:INN]
- UNII-SMA5ZS5B22
- ENSARTINIB [WHO-DD]
- orb1692764
- orb3033026
- SCHEMBL15131489
- SCHEMBL29358463
- SCHEMBL29489149
- SCHEMBL29716660
- BDBM179297
- GLXC-15836
- EX-A2941
- NSC793150
- s8230
- AKOS040755918
- CCG-270051
- NSC-793150
- NCGC00599613-01
- DA-73120
- HY-103714
Look up ENSARTINIB in the interactive SynDRA portal →